Solid Biosciences Inc.

NASDAQ:SLDB

Biotechnology

Healthcare
$6.23 +3.63%

+$0.27 today

Market cap
$695.33M
Beta
2.43
P/E (TTM)
-4.3
EPS (TTM)
-$1.75
52W Low $3.79High $8.87

Volume 1.13M

Average 1.39M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$156.29M

FY 2025 · Annual

Investing Cash Flow

-$58.45M

FY 2025 · Annual

Financing Cash Flow

$194.45M

FY 2025 · Annual

+58.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(72.19M)(85.98M)(96.02M)(124.7M)(174.33M)
Depreciation & Amortization2.96M2.41M2.58M2.46M(1.87M)
Deferred Income Tax1.21M0000
Stock-Based Compensation13.37M7.54M7.63M10.52M16.91M
Change in Working Capital(23.04M)(3.69M)(6.34M)2.85M(6.82M)
Accounts Receivables(110K)110K000
Inventory(11.5M)0000
Accounts Payables1.21M(5.25M)(764K)2.21M(1.09M)
Other Working Capital(12.64M)1.45M(5.57M)645K(5.73M)
Other Non-Cash Items(81K)(18.25M)(2.03M)8.86M9.82M
Operating Cash Flow(77.76M)(97.98M)(94.18M)(100.01M)(156.29M)
Capital Expenditures(1.28M)(3.02M)(1.52M)(654K)(1.15M)
Acquisitions (Net)89.81M31.52M05K85K
Purchases of Investments(141.25M)(182.76M)(117.43M)(204.34M)(235.89M)
Sales of Investments51.44M212.81M128.63M188.9M178.5M
Other Investing Activities(89.81M)600K000
Investing Cash Flow(91.09M)59.16M9.69M(16.09M)(58.45M)
Debt Repayment02.08M0(473K)(723K)
Common Stock Issued134.88M72.55M2.97M127.23M194.74M
Common Stock Repurchased000(5.11M)0
Dividends Paid00000
Other Financing Activities107K203K148K794K425K
Financing Cash Flow134.99M74.83M3.12M122.44M194.45M
Effect of Forex Changes00000
Net Change in Cash(33.87M)36.01M(81.37M)6.34M(20.3M)
Free Cash Flow(79.05M)(100.99M)(95.7M)(100.67M)(157.44M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$174.3M
+ D&A-$1.9M
+ Stock-Based Comp$16.9M
+ Deferred Tax$0
- Working Capital-$6.8M
+ Other Non-Cash$9.8M
= Operating Cash Flow-$156.3M
- Capex-$1.2M
= Free Cash Flow-$157.4M

Analysis

FY2025 free cash flow is -$157.4M. FCF conversion is 90.3% of net income. Operating cash flow was -$156.3M, with capex of -$1.2M. The largest bridge item is Stock-Based Comp at $16.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13D/ASC 13D/A filingNov 6, 2026
10-QQuarterly reportNov 4, 2026
4Statement of changes in beneficial ownershipOct 26, 2026
4Statement of changes in beneficial ownershipOct 20, 2026
4Statement of changes in beneficial ownershipOct 6, 2026

Does SLDB generate free cash flow?

Solid Biosciences Inc. (SLDB) generated -$157.44M of free cash flow in fiscal 2025.

How much operating cash flow does SLDB produce?

Operating cash flow was -$156.29M, before capital expenditures of $1.15M.